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The original helical ArcCHECK (AC) diode array and associated software for 
3D measurement-guided dose reconstruction were characterized and validated; 
however, recent design changes to the AC required that the subject be revisited. 
The most important AC change starting in 2014 was a significant reduction in the 
overresponse of diodes to scattered radiation outside of the direct beam, accom-
plished by reducing the amount of high-Z materials adjacent to the diodes. This 
change improved the diode measurement accuracy, but in the process invalidated 
the dose reconstruction models that were assembled based on measured data 
acquired with the older version of the AC. A correction mechanism was intro-
duced in the reconstruction software (3DVH) to accommodate this and potential 
future design changes without requiring updating model parameters. For each 
permutation of AC serial number and beam model, the user can define in 3DVH a 
single correction factor which will be used to compensate for the difference in the 
out-of-field response between the new and original AC designs. The exact value 
can be determined by minimizing the dose-difference with an ionization chamber 
or another independent dosimeter. A single value of 1.17, corresponding to the 
maximum measured out-of-field response difference between the new and old 
AC, provided satisfactory results for all studied energies (6X, 15X, and flatten-
ing filter-free 10XFFF). A library of standard cases recommended by the AAPM 
TG-244 Report was used for reconstructed dose verification. The overall difference 
between reconstructed dose and an ion chamber in a water-equivalent phantom in 
the targets was 0.0% ± 1.4% (1 SD). The reconstructed dose on a homogeneous 
phantom was also compared to a biplanar diode dosimeter (Delta4) using gamma 
analysis with 2% (local dose-error normalization) / 2 mm / 10% cutoff criteria. The 
mean agreement rate was 96.7% ± 3.7%. For the plans common with the previous 
comparison, the mean agreement rate was 98.3% ± 0.8%, essentially unchanged. We 
conclude that the proposed software modification adequately addresses the change  
in the dosimeter response.
PACS number(s): 87.55Qr
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I. INTRODUCTION
The ArcCHECK (AC), developed by Sun Nuclear Corp., Melbourne, FL, is a diode-array 
dosimeter used primarily for quality assurance of IMRT/VMAT treatments. It can be employed 
by itself to compare measured and reference dose at the detectors’ locations(1-6) or in conjunction 
with 3DVH software (Sun Nuclear) that uses a AC-based planned dose perturbation (ACPDP) 
algorithm to perform volumetric measurement-guided dose reconstruction on a phantom or 
patient dataset.(7-11) While the dosimeter and associated software have been characterized and 
employed rather extensively,(1-3,5,7,9,10,12-18) two recent developments necessitated revisiting 
the subject.
First, there have been several design changes in the AC hardware since the original calibra-
tion factors(5) and 3DVH beam models(7) were validated. These changes were implemented to 
improve device performance and regulatory compliance, but it was suspected that some of the 
changes could influence the dosimeter response characteristics, which would naturally change 
the volumetric dose reconstruction with 3DVH. The reconstruction procedure was optimized 
based on the original AC design. It is good practice to repeat the basic characterization of the 
array, to rule out (or mitigate if necessary) any unexpected effects and verify the intended 
improvements. In addition, while the practical use of the AC with 10 MV flattening filter-free 
beam has been reported,(19) the comprehensive evaluation has not.
Second, in departure from the previous school of thought,(20) the AAPM TG-244 Report on 
medical physics practice guidelines for commissioning of dose calculations(21) allows the use of 
electronic dosimetry arrays as a primary commissioning tool for evaluating IMRT/VMAT dose 
distributions, provided that dose measurement or reconstruction is performed with adequate 
spatial resolution. Furthermore, TG-244 makes challenging, patient-based cases (image sets, 
structure sets, and detailed lists of dosimetric objectives) available for download to be used 
for commissioning of the IMRT/VMAT systems. It would be useful for the clinical physics 
community to have a benchmark of the level of dosimetric agreement achievable with the AC 
and 3DVH for these cases. Unlike the previously reported TG-119 datasets,(22) the TG-244 
ones are more clinically relevant and include fairly large target volumes, which are known to 
be challenging for the TPS calculation accuracy. Finally, TG-244 suggests more stringent dose 
comparison metrics be employed in addition to the ubiquitous(20,23) 3% (global dose-error nor-
malization) / 3 mm distance-to-agreement gamma passing rates that were used in the TG-119 
report,(22) but since then have been largely proven to be neither sensitive nor specific.(18,24-28)
 
II. MATERIALS AND METHODS
A.  General
All measurements were performed with conventional (6X and 15X) and flattening filter-free 10X 
(10XFFF) beams from a TrueBeam v 2.0 linear accelerator equipped with a 120-leaf Millennium 
multileaf collimator (MLC) from Varian Medical Systems, Palo Alto, CA. The treatment plan-
ning system (TPS) was Pinnacle v. 9.8 (Philips Radiation Oncology Systems, Fitchburg, WI).
The AC features an array of 1,386 point detectors that form a 10.4 cm radius cylindrical 
active surface inside a doughnut-shaped PMMA phantom. The phantom has an outer diameter 
of 26.6 cm and a 15 cm diameter inner hole that can be plugged with a PMMA cylinder.(5) All 
tests in this work were performed with the plug inserted, as this is the configuration necessary 
for 3D dose reconstruction.(7) The phantom was represented in the TPS by a cylinder with a 
uniform relative density of 1.15, which was shown previously to provide adequate agreement 
between the ion chamber measurements and TPS calculations.(5)
ArcCHECK measurement data were collected using SNC Patient software v. 6.6 (Sun 
Nuclear Corp). Statistical analyses were performed with GraphPad Prism software package 
(v. 6, GraphPad Software, La Jolla, CA).
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B.  ArcCHECK hardware changes
The original AC is designated by the manufacturer as Version 1, while the redesigned one, 
subject of the current investigation, is Version 2. Version 2 began shipping in 2014, in part to 
meet the European Union hazardous substances mandate.(29) One difference between the “old” 
(v.1) and “new” (v.2) AC hardware is a redesign of the readout electronics. An onboard buf-
fer memory, in combination with a more robust interface and connection cable, ensures better 
reliability of 50 ms updates recording. The new electrometers are more sensitive and also more 
stable with respect to zero drift, both features particularly advantageous for longer and/or low 
dose rate measurements. 
The second major change — the one that directly affects the dosimeter response — was a 
reduction in the overall amount of high-atomic-number materials, particularly lead, used in 
diode and printed circuit board manufacturing. Also, wherever possible, metal conductors were 
placed farther away from the sensitive volumes. Since the energy dependence of the diode is 
largely determined by the surroundings of the die,(30) the impact on detector response had to 
be thoroughly investigated. 
C.  Basic dosimeter properties
A full dosimetric characterization of the new AC was performed, as warranted by significant 
design changes. However, for brevity we will only elaborate here on those tests that have not 
been performed before either at all or for certain energies, or produced results substantially 
different from the v. 1 AC.
C.1  Dosimetric tests with no substantial new findings
The tests in this category included: a classic relative calibration test (the 180° “detector flip”);(3,31) 
a diode sensitivity as a function of field size test; and diode sensitivity as a function of posi-
tion in transverse and longitudinal directions tests. In all cases the device performed within 
specifications and/or substantially equivalent to the previous version.(4,5,14)
C.2  Dose and dose-rate dependencies
The AC diodes are potentially subject to a variety of sensitivity changes related to both the 
accumulated dose and dose rate, as described below.
C.2.1 Low MU linearity
With the central plug in place, the AC exit dose is about one-quarter of the entrance one. 
Therefore the dose linearity has to be studied separately for different diode positions. The 
relative AC response for the entrance and exit diodes in a 10 × 10 cm2 6X beam was studied in 
the 1–100 MU range against the ion chamber. Because of the known long-lived trap popula-
tion effect,(32) these measurements were performed with two SNC Patient software settings. At 
first the default parameters were used, whereby the beam-on recognition was turned on and 10 
measurement updates (every 50 ms) were collected after the beam-off flag. In the subsequent 
measurement series, effectively all the updates were collected, whether the beam was on or off.
C.2.2 Dose per pulse
Diode sensitivity variation with dose per pulse (DPP) was measured against the IC by varying 
the source-to-detector distance (SDD). Within the studied SDD range from 74.6 to 119.6 cm, 
the dose per pulse changed from approximately 2 × 10-4 to 5 × 10-4 Gy for the 6X beam and 
from 2 × 10-3 to 6 × 10-3 Gy for 10XFFF. The AC or the dummy shell with the IC were irradi-
ated by a vertical beam and the readings were taken at the entrance (average of X = ± 5 mm 
for the AC). The normalized ratios of AC dose to IC reading were recorded.
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C.2.3 Repetition rate 
The accelerator repetition rate (MU/min) dependence was studied less frequently than dose per 
pulse one. However, such dependence for the AC diodes does exist(5) and was hypothesized by 
Jursinic(32) to be attributable to the capture of excess minority carriers by charge traps. The slow 
reopening of these traps should occur on the hundreds of milliseconds to seconds time scale 
to serve as the physical basis for the repetition rate dependence. The repetition rate was varied 
from 5 to 600 MU/min for the 6X beam and from 400 to 2400 Mu/min for 10XFFF, extending 
the repetition rate range compared to the previous reports.(4,5) The diode doses were divided 
by the corresponding IC readings, and normalized at 400 MU/min, a common repetition rate 
setting for both X-ray energies.
C.3  Out-of-field sensitivity 
Being not water-equivalent, diode detectors have energy dependence, and one of the manifesta-
tions of this fact is a variation in sensitivity with the distance from the aperture edge outside 
the direct beam, due to the energy spectrum changes. The change in sensitivity to scattered 
low-energy photons is the largest difference between the two AC designs that is apparent to the 
end user. To quantify the changes, the diode-loaded AC (v.1 and then v.2) and the dummy AC 
shell with the ion chamber were aligned at the isocenter and then slightly rotated to place the 
sensitive volume at the central axis. A series of the MLC apertures were designed. They varied 
from 0.5 to 3 cm in width and were positioned such that the measurement point was either 1 or 
2 cm outside the field. The AC diode and the IC readings were normalized to their respective 
open 10 × 10 cm2 fields values, and the AC/IC ratios were plotted for the 6X and 15X beams.
D.  Three-dimensional dose reconstruction
D.1  3DVH software changes
D.1.1 Background
3DVH software uses time-resolved dose information from the AC to generate high density 
3D dose grids. Necessary to this process is a library of beam models, each of which is unique 
for specific linac/energy/MLC combinations.(7) These models are essential to create a high 
density, high resolution dose grid for each subbeam, that can then be perturbed to fit the cor-
responding measurements at the entry and exit surfaces.(7) The model library was developed 
based on measurements from the AC v.1. The AC data acquisition software currently does not 
include an explicit correction for the diode out-of-field (OOF) overresponse. Therefore this 
overresponse was implicitly accounted for in the volumetric reconstruction model, to ensure 
favorable comparison with the independent IC measurements inside the volume. Consequently, 
if/when the OOF sensitivity changes with new hardware designs, the method’s original com-
pensation for overresponse is no longer optimized and would lead to erroneous results. While 
it is theoretically possible to create different model versions that are specific to each new AC 
hardware configuration, this would be prohibitive from the product maintenance standpoint. 
Instead, the strategy was to keep the existing, universal library of beam models and provide a 
simple correction mechanism to tune it for a particular AC version. A correction factor can now 
be assigned by the user for each distinct combination of the AC hardware version (identified 
by serial number) and 3DVH beam model. This correction factor is a single, relative value that 
essentially quantifies the difference in response to the OOF radiation between the new original 
AC designs. The default correction of 1.0 means “no change”, but for any other value, a special 
correction takes place during the reconstruction of each time-resolved subbeam’s absolute dose. 
Taking the current AC design change as an example, the beam model that compensated for the 
original overresponse now overcompensates. Left uncorrected, ACPDP dose would be system-
atically low even though the measurement data are technically more accurate. The purpose of 
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the correction is simply to dampen the compensation and “add back” small amounts of dose, 
but only in the areas of each subbeam that are under an MLC leaf and/or jaw.
D.1.2 Correction method
The straightforward solution would be to split the 3D dose into primary (i.e., transmission) and 
scatter components for every reconstructed subbeam, then correct only the scatter component. 
We implemented this method at first, only to realize that it caused a marked increase in the dose 
reconstruction time. Therefore, we implemented a simplified and fast method. This approach 
creates a single 2D correction mask for each reconstructed subbeam, where the mask is in a 
beam’s-eye-view (BEV) sense perpendicular to the beam axis, following divergent lines from 
the source. The correction mask is constant over all depths but tapered to unity at the curved 
entry and exit surfaces of the diode array. The dose reconstruction time using the simplified 
method was, on average, within 10% of the original (i.e., uncorrected) calculation time.
The dose correction factor for any point (x,y,z) in the beam coordinate system for a modulated 
subbeam is summarized by the equations below. 
 Dose
sub – beam, corrected
(x,y,z) = Dose
sub – beam, uncorrected
(x,y,z) * 
  Composite OOF Correction (x,y) 
(1)
where x and y are the ray position coordinates in BEV and z is the orthogonal (depth) coordinate. 
The last term in Eq. (1) is defined as 
  (2)
 
Composite OOF Correction (x,y) = 
[Corrected Fluence (x,y,MU)  dMU]
MU end
MU start
∫
[Uncorrected Fluence (x,y,MU)  dMU]
MU end
MU start
∫
The MU parameter represents the dynamic progression for modulated beams derived from the 
meterset progression in the DICOM RT Plan. Integration (summation) is performed from start 
to end of each subbeam. Uncorrected Fluence for any x, y point is a measure of “exposure” to 
the beam, or cumulative time a point spends inside an open aperture (1.0 contribution) relative 
to being under an MLC leaf (contribution equals MLC transmission fraction). This value is 
then corrected:
 Corrected Fluence (x,y,MU) = Uncorrected Fluence (x,y,MU) +
  OOF Adjustment (x,y,MU) 
(3)
In turn,
  (4)
 
OOF Adjustment (x,y,MU) 
(Nominal OOFCF – 1.0) * EDF,
0.0,
for regions under collimation
for directly irradiated regions, i.e. inside the momentary aperture
= {
where Nominal OOFCF is the nominal out-of-field correction factor (specified by the user on 
the software setup tab) and EDF is the energy dependence factor, a small fraction derived from 
the PDP model parameters. The EDF increases with energy but is always a small number, on 
the order of 0.01 to 0.025. This factor is introduced so that the user-defined Nominal OOFCF 
stays effectively the same across all energies, for ease-of-use.
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D.2  ACPDP comparisons with direct measurements 
D.2.1 Test plans
IMRT and VMAT plans were selected based on the TG-244 Report recommendations.(21) They 
included two well-known plans from the TG-119 suite(22) (C-shape and Mock Head and Neck 
(H&N), optimized on the 20 × 20 × 20 cm3 plastic water (PW) Cube Phantom from CIRS Inc., 
Norfolk, VA), and three more realistic plans from the downloadable datasets in the TG-244 
library:(21) Anal, H&N, and Abdomen. The concept behind the TG-244 cases is to provide 
challenging but clinically relevant goals, with large targets and tight constraints, resulting in 
highly modulated plans pushing the accuracy limits of the TPS calculation algorithms. These 
datasets were previously used for large, inter-institutional plan studies similar to the pilot study 
described by Nelms et al.(33)
All plans were optimized based on 6X beams and for the purpose of this work simply recal-
culated for other energies.(21) All plans were created with both VMAT (Pinnacle SmartArc) 
and step-and-shoot IMRT (Pinnacle Direct Machine Parameters Optimization) techniques. The 
TG-244 H&N and Anal VMAT plans used two arcs and the rest one. The VMAT plans were 
calculated with 2° angular control points (CP) increment. The IMRT plans used seven to nine 
equidistant gantry angles. Two of the plans (TG-244 H&N and Anal) had targets too large to be 
encompassed for conventional IMRT with a single set of Varian MLC carriage positions, due 
to the limitations of the MLC leaf extension. They were instead planned with the “wide-field” 
IMRT technique, where the leaves are allowed to nearly close inside the treatment field, not 
necessarily under the X jaws, but those leaf abutment points move across the field from seg-
ment to segment, to avoid excessive exposure at any one location in the patient. In all cases, 
uniform 2.5 mm dose grid resolution was used. 
D.2.2 ACPDP point dose comparisons
Point doses in the high-dose, low-gradient regions were measured in the PW Cube Phantom 
with a 0.125 cm3 Model TN31010 ion chamber (PTW, Freiburg, Germany). The chamber was 
cross-calibrated in a 10 × 10 cm2 field against the expected TPS dose prior to every measurement 
session. The chamber volume was drawn as a region of interest and the corresponding mean 
dose was used for comparisons. The confidence limit (CL) of the average difference between the 
measured and reconstructed dose was expressed as mean ± 1.96 standard deviation.(22,34) Note 
that this confidence limit is different (larger) than the traditional statistical confidence interval.
D.2.3 ACPDP dose distribution comparisons with a biplanar array
The ACPDP volumetric dose was directly compared to the applicable measurement planes of 
a previously validated biplanar dosimeter.(35-39) Excellent agreement between ACPDP recon-
structed dose (based on the original AC design) and Delta4 (ScandiDos AB, Uppsala, Sweden) 
measurements was demonstrated earlier.(10) Note that the Delta4 calibration formalism includes 
an adequate empirical software correction for the diode response variation outside the beam 
aperture.(37) It is however a second-order correction for the cumulative dose measurements.
The AC phantom with the plug was centered on the lasers. The daily correction factor was 
determined by comparing measured and calculated doses in the central portion of the parallel-
opposed 10 × 10 cm2 field pair, at the midrange repetition rate.(5,32) Three-dimensional ACPDP 
dose reconstruction was performed with a prototype version of 3DVH software incorporating 
OOF corrections as described above. The cylindrical Delta4 phantom represented the “patient” 
dataset used for dose reconstruction.(10) The reconstructed dose grid was saved in DICOM RT 
Dose format and imported into the Delta4 software as reference dose. After the treatment was 
delivered to the Delta4 in a usual fashion, the reconstructed dose was compared to direct mea-
surement using built-in gamma analysis tools.(40) Both 3%/2 mm and 2%/2 mm criteria com-
binations were used, with global (e.g., 3% G) and local (e.g., 3% L) dose-error  normalization. 
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Low dose analysis threshold was 10% of the maximum. For conciseness, only the results with 
2% dose-error criteria are presented in detail when comparing the AC to the Delta4.
D.2.4 Comparisons with the TPS
One of the goals of this paper, in addition to validating the modified ACPDP hardware and 
software, is to estimate the range of achievable gamma analysis results on a phantom for the 
TG-244 datasets, which unlike TG-119,(22) have not been extensively studied so far. To that end, 
we present the data for both the direct AC to TPS comparison and the comparison between the 
3D ACPDP and TPS dose grids. In this case, the results of gamma analysis with 3% G/2 mm are 
also included, as this seems to be the emerging criteria combination for patient-specific IMRT 
QA. Following the TG-119 methodology,(22) the 95% one-sided confidence CL is established 
for the gamma analysis passing as 100% - (mean passing rate) - 1.96*(standard deviation).(22)
 
III. RESULTS AND DISCUSSION
A.  Basic dosimeter properties
A.1  Dose and dose rate dependencies
A.1.1 Low MU linearity
The results are presented in Fig. 1. The deviation from the straight line for the 2 MU setting 
(entrance diode) is -2.8%, somewhat larger than the -0.9% error reported by Li et al.(14) for the 
comparable data point with the AC v.1. Since for the same MU setting the exit dose is about 
one-quarter of the corresponding entrance one, the apparent nonlinearity of response is more 
pronounced for the exit diodes. Extending the integration time (modified vs. default settings 
curves in Fig. 1) reduces the maximum nonlinearity by approximately one-half, consistent 
with the notion that shorter integration time prevents all the charge trapped in the long-lived 
centers from being collected. 
The residual nonlinearity is likely associated with the intrinsic diode properties(32) rather 
than the readout electronics, since similar effects were reproduced with this type of diode con-
nected to a variety of electrometers in different devices. It was also verified by the ion chamber 
measurements at the different depths in a phantom that the observed effect is not caused by the 
possible initial beam instability during short exposures. The investigated version of AC (v.2) 
has a more robust background and zero-drift suppression that its predecessor, and therefore the 
modified settings with long integration times were used for subsequent data collection. Longer 
Fig. 1. Low MU nonlinearity. AC exit and entrance doses are normalized to the ion chamber and shown as a function of MU. 
The default software settings limit the number of updates after the beam is turned off, while the modified settings do not.
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integration times should become the default for the AC v.2. Current findings agree with the AC 
specifications of < 0.5% integration non-linearity from 6 to 30 cGy total dose.(41) However, it 
must be noted that, for the 6X beam, the exit dose with the plug is approximately 0.3 cGy/MU 
and thus the specifications do not address dose linearity for segments with less than ~ 20 MU, 
which are quite common with standard fractionation. The results in Fig. 1 provide the nonlin-
earity estimates down to 1 MU.
A.1.2 Dose per pulse
Within the studied SDD range from 74.6 to 119.6 cm, the AC/IC ratio varied smoothly from 
1.012 to 0.992, and from 1.001 to 0.995 for the 6X and 10X FFF beams, respectively. The ratios 
were normalized to 1.000 at the calibration SDD of 89.6 cm. The overall change in response 
of ~ 2% for the 6X beam is substantially smaller than reported by Chaswal et al.(4) Their 7% 
variation for the same SDD range, based on the inverse-square dose estimates, appears exces-
sive compared to the previous reports studying similar diodes.(14,31,42) We believe that the 
methodology of direct comparison with recombination-corrected IC employed in this work 
is a well-established standard for these types of measurements and provides a more realistic 
estimate of the SDD dependence, in line with the previous findings. With the 10X FFF dose 
per pulse being approximately an order of magnitude higher than 6X, the large percentage of 
the charge traps remain populated regardless of the SDD within the studied limits, and there 
was little change in diode sensitivity. 
A.1.3 Repetition rate
The AC response relative to the IC as a function of repetition rate is presented in Fig. 2. 
Normalized at 400 MU / min, the curve is relatively smooth, with two different energies used 
for the low and high end of the repetition rate range. For the lowest (5 MU / min) repetition 
rate the AC/IC ratio was 0.978, which is reasonably close to the previously reported value of 
0.986.(5) The difference did not exceed 1% for the 100–600 MU/min range with the 6X beam 
and the entire 400–2400 MU/min range with the 10X FFF beam.
A.2  Out-of-field sensitivity 
Normalized ratios of the AC to IC readings outside the field are presented in Figs. 3(a) and 3(b). 
Since the amount of scattered radiation reaching the point of measurement increases with the 
field size and decreases with the distance to the field edge, it is natural that the relative sensi-
tivity of the diode would generally increase as shown in Fig. 3. With the exception of one data 
point, the ratio of AC to IC stays fairly flat for the given hardware version, namely within 1%. 
It is clear from Fig. 3 that the AC v.2 has substantially lower overresponse outside the field, 
which is consistent with the reduction in the amount of high-Z materials present in the newer 
Fig. 2. Repetition rate dependence for the 6X and 10X FFF beams. The AC/IC ratio is normalized at 400 MU/min.
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design. In comparison with the previous work,(4) we believe that directly referencing the ion 
chamber provides a more realistic overresponse estimate than their TPS-based analysis. The 
out-of-field response was also reported in 2013, presumably for the v. 1 of the AC, by Li et 
al.(14) The differences in the geometry preclude detailed comparisons of the results, but under 
the most similar conditions, our factor for the AC v. 1 appears to be about 10% higher.
The OOF sensitivity change is a second-order effect which has limited practical consequences 
when the dosimeter is used to directly compare the diode dose to the TPS. However, it becomes 
important when the apparent AC dose profiles are used to determine the dose-spread kernel 
parameters for internal calculations during volumetric dose reconstruction. The results above 
clearly support the need for the additional correction factor in the 3D dose-reconstruction software.
Fig. 3. Ratios of readings at the points 1 and 2 cm outside the field as a function of the aperture width: AC to IC ratios for 
(a) the old (v.1); (b) the new (v.2) versions of the ArcCHECK; (c) the ratios of the v.1 to v.2 AC readings.
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B.  Three-dimensional dose reconstruction
B.1  Selection of the overresponse correction factor in the software
The ratio of the old to new AC diode overresponse from Fig. 3 varied from 1.0 to 1.17 between 
all geometries and the two extreme energies (6X and 15X). In the search of the simplest practical 
solution, we elected to use the highest value (1.17) as the starting point, the rationale being that 
the points with the largest amount of scatter are likely to have the highest OOF absolute dose 
and thus have the most influence on the final results. This value was further refined by varying 
the correction factor to maximize the 2% L/2 mm gamma analysis agreement rate and minimize 
the median dose deviation for one dataset (TG-119 C-shape) between the ACPDP on the Delta4 
phantom and direct Delta4 measurements. This was done for both 6X plans, VMAT and IMRT. 
As one can see in Fig. 4, the median dose difference is minimized around the OOFCF of 1.17, 
while the passing rates nearly plateau. Since the maximum measured value was 1.17, it was 
logical not to exceed that value. 
B.2  ACPDP comparisons with direct measurements 
B.2.1 Point-dose comparisons
The average difference for all plans and energies between the ACPDP dose reconstructed on the 
PW Cube and the ion chamber measurement in the high-dose low-gradient regions was 0.0% ± 
1.4% (95% CL -2.7% to 2.7%). The distribution passed the D’Agostino & Pearson omnibus 
normality test and the mean was not statistically significantly different from 0 (t-test p = 1.0).
Fig. 4. Gamma analysis passing rates (a) (2% L/2 mm) and median dose-differences (b) for 6X IMRT and VMAT plans, 
comparing ACPDP with the Delta4 as a function of user-selectable out-of-field correction factor (OOCF).
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For practical implementation of the modified software with the wider user base, whereby an 
independent array dosimeter may not be readily available, similar ion chamber measurements 
are likely to be the primary means of establishing the correction factor. They can be performed 
in either an arbitrary phantom, as was done here, or with the standard single-hole PMMA plug 
in the AC phantom, or with the optional Multi-Plug that provides a variety of possible chamber 
locations throughout the reconstruction volume.(11)
B.2.2 Comparisons with a biplanar array
The detailed results are presented in Table 1. The overall mean agreement rate at the most strin-
gent level of 2% L/2 mm gamma analysis is 96.7% ± 3.7% (1 SD), which appears somewhat 
lower than reported with the previous AC/3DVH version (98.2% ± 1.6%).(10) However, a closer 
look reveals that for the plans common to both investigations (TG-119 C-shape and H&N), the 
mean agreement rate for all energies and techniques is 98.3% ± 0.8%, essentially unchanged 
from the previous report. Likewise, the TG-244 Abdomen plan passing rate is 98.5% ± 1.6%. 
The lower agreement rates that pull down the average are associated only with the larger targets 
Table 1. Gamma analysis passing rates and median dose-differences for 3D ACPDP on the Delta4 phantom vs. Delta4 
directly measured dose.
 ACPDP vs. Delta4 γ Passing Rate (%)
   Local Dose-error Global Dose-error Median ΔD
 Dataset Energy/Technique 2%/2 mm 2%/2 mm (%)
 Abdomen-TG 244 6X-VMAT 100.0 100.0 0.2
  6X-IMRT 98.2 100.0 0.3
  15X-VMAT 100.0 100.0 -0.1
  15X-IMRT 99.1 99.8 0.0
  10XFFF-VMAT 95.9 96.6 -0.9
  10XFFF-IMRT 97.5 99.2 -0.5
 H&N-TG 244 6X-VMAT 96.2 98.3 0.4
  6X-WFIMRT 96.0 97.9 0.3
  15X-VMAT 98.7 99.6 -0.1
  15X-WFIMRT 99.2 99.9 -0.1
  10XFFF-VMAT 84.4 92.7 1.3
  10XFFF-WFIMRT 87.8 94.4 1.3
 Anal-TG 244 6X-VMAT 99.1 100.0 -0.1
  6X-WFIMRT 94.7 97.1 -0.1
  15X-VMAT 98.0 99.0 -0.6
  15X-WFIMRT 91.8 96.8 -0.8
  10XFFF-VMAT 93.3 98.5 0.7
  10XFFF-WFIMRT 91.1 96.7 0.7
 C-shape-TG 119 6X-VMAT 98.0 99.5 -0.1
  6X-IMRT 98.4 99.4 0.4
  15X-VMAT 98.9 99.8 -0.3
  15X-IMRT 99.1 99.2 0.6
  10XFFF-VMAT 97.3 99.0 -0.7
  10XFFF-IMRT 99.8 100.0 -0.5
 H&N-TG 119 6X-VMAT 97.5 99.4 -0.4
  6X-IMRT 97.3 99.7 0.5
  15X-VMAT 98.2 99.2 -0.3
  15X-IMRT 98.6 99.8 0.4
  10XFFF-VMAT 97.7 98.8 -0.4
  10XFFF-IMRT 99.2 100.0 0.0
   Average 96.7 98.7 0.0
  SD 3.7 1.8 0.6
  Min 84.4 92.7 -0.9
  Max 100.0 100.0 1.3
174  Ahmed et al.: Validation of helical array 174
Journal of Applied Clinical Medical Physics, Vol. 17, No. 6, 2016
(TG-244 H&N and Anal plans), particularly with the 10X FFF beam. The worst agreement at 
the 2% L/2 mm level is observed for the TG-244 H&N plans with 10X FFF. With both VMAT 
and IMRT, the median dose difference between the ACPDP and Delta4 in those cases is 1.3%, 
the largest in the population. On the other hand, the median dose difference averaged across 
all plans and energies is 0.0% ± 0.6%, with the 95% CL from -1.2% to 1.2% and the distribu-
tion passing the normality test. In conjunction with the IC data presented above, this confirms 
the choice of a single value for the overresponse correction described in the previous section. 
Relaxing the criteria to 3% L/2 mm results in the average γ analysis agreement rate between 
the ACPDP and Delta4 of 98.3% ± 2.2%, with only four data points below 95% and none 
below 92%.
The modification to 3DVH software was definitely necessary. Without it, the average ACPDP 
vs. Delta4 2% L/2 mm and 2% G/2 mm agreement rates would have been unacceptable: 73% 
and 78%, respectively, with a bias of ACPDP dose being too low.
B.2.3 Comparisons with the TPS
As a point of reference, the average difference between the TPS and IC was 0.6% ± 0.9% (95% 
CL -1.2% to 2.4%). The distribution did not pass the normality test (p = 0.01) and the mean 
value is statistically significantly different from 0.0 (t-test p = 0.001). Despite this slight bias, 
the mean value is comfortably below 1.5% reported or recommended for the high dose regions 
by the relevant task groups.(21,22)
The results of the direct AC to TPS comparison, and the comparison between the 3D ACPDP 
and TPS dose grids are presented in Table 2 and Table 3, respectively. Following the TG-119 
confidence limit methodology, for the 3% G/2 mm criteria, in 95% of the cases one should 
expect at least 96.3% of the points to pass with the AC and 96.9% with the ACPDP. This is 
above the proposed 95% investigative threshold, let alone the 90% actionable one. Moreover, 
the 90% pass action threshold should be exceeded or attained at the 95% confidence level 
even with the more stringent 2% G/2 mm criteria, for both the AC and ACPDP. Therefore it is 
expected that the well-commissioned TPS, in conjunction with the new ArcCHECK hardware 
and software, should consistently produce gamma analysis results acceptable by the emerg-
ing standard, whether for the basic AC measurements or for 3D ACPDP on a homogeneous 
cylindrical phantom. At the same time, the analyses with the more sensitive local dose-error 
criteria show reduced agreement, particularly with the larger targets from the TG-244 datas-
ets requiring wide-field IMRT. While the average 2% L/2 mm ACPDP vs. TPS passing rate 
is a respectable 91%, the two lowest values are 75.5% and 78.2%, for the 6X and 15X Anal 
wide-field IMRT plans, respectively. These types of plans contain complex bifurcating targets 
separated by large low-dose volumes and are known to be problematic in terms of dosimetric 
agreement, particularly in the low-dose areas when the local dose-error normalization is used. 
This is clearly illustrated in Fig. 5, where gamma analysis failures, save a few errand pixels, are 
confined to the areas outside the targets. Wide-field IMRT introduces an additional challenge 
of modeling the leakage through the static, narrow gaps between the nearly abutting MLC 
leaves inside the field. Thus the TG-244 plans serve as a useful stress test. While the ACPDP 
results obviously based on the AC measurements, the former shows a slightly better agreement 
with the TPS than the latter (Table 3 vs. Table 2), both in terms of the average gamma passing 
rates and average median dose-difference across the plan population. This is consistent with 
the notion that the AC has an inherently challenging geometry for comparison with the TPS. 
Given the peripheral detector location, the AC measured dose is typically considerably lower 
than the central one. The 10% low dose cutoff threshold becomes perhaps 5% or so in a global 
sense, making it more difficult to achieve agreement with the TPS, exceedingly so with the local 
dose-error normalization. The sign of the average median dose deviation (AC > TPS) suggests 
that further reducing the AC dose-response nonlinearity with low MU would not improve the 
results, since it would increase the reported dose, if anything.
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Overall, the comparison results, whether with another array dosimeter or the TPS, underscore 
the ultimate dilemma one faces with the intensity-modulated dose distribution measurements: 
the expected accuracy of the measurement tool (~ 2%) is comparable to the desired uncertainty 
in the measured quantity (2%–3% in dose), instead of being an order of magnitude smaller, as 
dictated by metrology. A relatively small systematic measurement error of say 0.5% can easily 
have a noticeable effect.
 
Table 2. Gamma analysis passing rates and median dose-differences: ArcCHECK vs. TPS.
 ArcCHECK vs. TPS γ Passing Rate (%)
   Local Global
   Dose-error Dose-error Median ΔD
 Dataset Energy/Technique 2%/2 mm 2%/2 mm 3%/2 mm (%)
 Abdomen-TG 244 6X-VMAT 93.7 99.8 100.0 1.1
  6X-IMRT 86.3 97.9 99.4 1.5
  15X-VMAT 94.8 99.8 100.0 1.1
  15X-IMRT 89.2 98.0 99.4 1.1
  10XFFF-VMAT 98.0 100.0 100.0 -0.2
  10XFFF-IMRT 92.0 97.1 98.8 -0.6
 H&N-TG 244 6X-VMAT 86.2 98.5 100.0 1.3
  6X-WFIMRT 78.3 95.4 98.9 2.3
  15X-VMAT 92.0 99.8 99.9 1.4
  15X-WFIMRT 81.8 95.8 99.0 2.3
  10XFFF-VMAT 92.1 98.4 99.3 -1.0
  10XFFF-WFIMRT 90.4 97.3 99.3 0.1
 Anal-TG 244 6X-VMAT 80.8 97.5 99.9 2.6
  6X-WFIMRT 73.4 92.1 98.0 2.9
  15X-VMAT 88.5 97.4 99.2 1.9
  15X-WFIMRT 83.1 94.5 98.6 2.3
  10XFFF-VMAT 92.1 98.9 99.6 -0.5
  10XFFF-WFIMRT 91.8 98.1 99.5 0.7
 C-shape-TG 119 6X-VMAT 80.6 93.4 97.5 2.6
  6X-IMRT 85.4 90.4 95.3 2.4
  15X-VMAT 86.3 95.4 98.6 1.7
  15X-IMRT 86.5 92.1 95.6 0.8
  10XFFF-VMAT 91.2 98.4 99.7 -0.3
  10XFFF-IMRT 90.2 95.2 97.2 -0.3
 H&N-TG 119 6X-VMAT 86.0 94.2 98.4 2.0
  6X-IMRT 89.0 94.1 98.4 1.0
  15X-VMAT 90.6 94.4 97.3 1.0
  15X-IMRT 92.5 95.4 98.1 0.5
  10XFFF-VMAT 91.2 95.3 97.4 -0.5
  10XFFF-IMRT 88.8 94.0 97.8 -1.1
   Average 88.1 96.3 98.7 1.0
  SD 5.3 2.6 1.2 1.2
  Min 73.4 90.4 95.3 -1.1
  Max 98.0 100.0 100.0 2.9
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Table 3. Gamma analysis passing rates and median dose-differences: ACPDP vs. TPS (on the 22 cm diameter Delta4 
PMMA phantom).
 ACPDP vs. TPS γ Passing Rate (%)
   Local Global
   Dose-error Dose-error Median ΔD
 Dataset Energy/Technique 2%/2 mm 2%/2 mm 3%/2 mm (%)
 Abdomen-TG 244 6X-VMAT 97.5 99.7 100.0 0.6
  6X-IMRT 94.7 99.6 99.9 1.1
  15X-VMAT 97.9 99.1 99.9 -0.3
  15X-IMRT 95.0 98.4 99.7 0.2
  10XFFF-VMAT 98.3 99.8 100.0 -0.6
  10XFFF-IMRT 91.1 98.9 99.9 -1.1
 H&N-TG 244 6X-VMAT 90.2 98.1 99.9 0.7
  6X-WFIMRT 83.7 93.4 99.5 1.0
  15X-VMAT 92.2 98.7 100.0 1.0
  15X-WFIMRT 85.2 95.8 99.4 1.6
  10XFFF-VMAT 90.3 95.9 99.5 -1.6
  10XFFF-WFIMRT 91.8 97.1 99.7 -0.9
 Anal-TG 244 6X-VMAT 82.7 93.3 99.3 2.5
  6X-WFIMRT 75.5 84.1 93.2 3.1
  15X-VMAT 87.3 96.5 99.8 2.3
  15X-WFIMRT 78.2 87.1 94.9 2.9
  10XFFF-VMAT 95.2 99.5 99.9 -0.5
  10XFFF-WFIMRT 92.6 98.3 99.6 0.5
 C-shape-TG 119 6X-VMAT 87 96.7 99.1 2.3
  6X-IMRT 89.6 97.5 99.3 1.5
  15X-VMAT 91.3 98.8 99.7 1.6
  15X-IMRT 89.3 95.9 98.5 0.9
  10XFFF-VMAT 93.5 98.5 99.7 0.4
  10XFFF-IMRT 93.2 98.6 99.7 0.5
 H&N-TG 119 6X-VMAT 94.8 99.2 99.9 1.3
  6X-IMRT 95.8 98.9 99.9 0.3
  15X-VMAT 94.6 98.9 99.8 0.9
  15X-IMRT 93.6 97.7 99.5 0.8
  10XFFF-VMAT 95.3 98.6 99.7 0.1
  10XFFF-IMRT 93.4 98.9 99.9 -0.7
  Average 91.0 97.1 99.3 0.7
  SD 5.5 3.6 1.5 1.2
  Min 75.5 84.1 93.2 -1.6
  Max 98.3 99.8 100.0 3.1
Fig. 5. A coronal cross section for a wide-field IMRT anal plan. The color coding over the dose-intensity map indicates 
the areas in the low-dose region that fail 3% L/2 mm gamma analysis (ACPDP vs. TPS).
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IV. CONCLUSIONS
We comprehensively characterized the redesigned ArcCHECK helical dosimeter and dose 
reconstruction software. Previously unreported response nonlinearity with low MU settings 
has been quantified. Increasing the integration period compared to the current default setting 
is recommended to minimize the effect. While most AC parameters did not change apprecia-
bly compared to the previous versions, the out-of-field diode response did. The overresponse 
to scattered out-of-field radiation has decreased by as much as 17% due to the reduction of 
the amount of high-Z materials in the immediate vicinity of the diodes. While objectively an 
improvement in the measurement accuracy, this change made the device incompatible with 
the existing 3D dose reconstruction software, which had to be redesigned to accommodate this 
and possible future changes. During the dose reconstruction software commissioning process, 
the user has to establish a single, energy-independent, correction factor appropriate for the 
ArcCHECK hardware and software versions. After the application of such factor in this work, 
the accuracy of measurement-guided dose reconstruction was restored to the previously reported 
level. In the process, we demonstrate with the challenging TG-244 commissioning datasets that 
ACPDP vs. Pinnacle TPS gamma-analysis passing rates on a homogeneous phantom can be 
expected to exceed 96% and 90% at the 95% confidence level, for the 3% G/2 mm/10% and 
2% G/2 mm/10%, respectively. The local dose-error normalization leads to wider variation in 
passing rates, with the larger targets presenting a challenge, as expected. Such TG-244 datasets 
provide a useful stress test for both the dosimeters and the TPS. They expand the availability 
of publicly available, standardized commissioning/verification cases, which are more clinically 
relevant and in some respects more probative than those from TG-119.
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